Natera Inc

More Details of Company

Company Info

Ticker SymbolNTRA

Company nameNatera Inc

IPO dateJul 02, 2015

CEOMr. Steven Leonard (Steve) Chapman

Number of employees4424

Security typeOrdinary Share

Fiscal year-endJul 02

Address13011 Mccallen Pass

CityAUSTIN

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code78753

Phone16502499090

Websitehttps://www.natera.com/

Ticker SymbolNTRA

IPO dateJul 02, 2015

CEOMr. Steven Leonard (Steve) Chapman

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.32M

-1.69%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

+0.01%

Mr. Jonathan Sheena

Co-Founder, Director

311.77K

-0.98%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

151.45K

-1.05%

Mr. John Fesko

President, Chief Business Officer

88.14K

+1.14%

Herman Rosenman, CPA

Independent Director

65.67K

+0.23%

Mr. Solomon Moshkevich

President - Clinical Diagnostics

46.21K

-6.67%

Dr. Monica Bertagnolli, M.D.

Independent Director

6.13K

+1.79%

Mr. Steven Leonard (Steve) Chapman

Chief Executive Officer, Director

4.42K

-68.63%

Mr. Michael Burkes Brophy

Chief Financial Officer

4.36K

-53.71%

Name

Name/Position

Position

Shareholding

Change

Dr. Matthew Rabinowitz, Ph.D.

Executive Chairman of the Board, Co-Founder

2.32M

-1.69%

Mr. Roelof Frederick Botha

Lead Independent Director

1.23M

+0.01%

Mr. Jonathan Sheena

Co-Founder, Director

311.77K

-0.98%

Mr. Daniel A Rabinowitz

Secretary, Chief Legal Officer

151.45K

-1.05%

Mr. John Fesko

President, Chief Business Officer

88.14K

+1.14%

Herman Rosenman, CPA

Independent Director

65.67K

+0.23%

Revenue Breakdown

Currency: USDUpdated: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Insurance carriers

472.65M

94.18%

Laboratory and other partners

20.83M

4.15%

Patients

8.35M

1.66%

By RegionUSD

Name

Revenue

Proportion

United States

492.31M

98.10%

Europe, Middle East, India, Africa

6.05M

1.21%

Asia Pacific and Other

1.78M

0.36%

Americas, excluding U.S

1.69M

0.34%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Insurance carriers

472.65M

94.18%

Laboratory and other partners

20.83M

4.15%

Patients

8.35M

1.66%

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.20%

T. Rowe Price Associates, Inc.

8.79%

JP Morgan Asset Management

6.50%

BlackRock Institutional Trust Company, N.A.

4.94%

Farallon Capital Management, L.L.C.

3.51%

Other

67.06%

Shareholders

Proportion

The Vanguard Group, Inc.

9.20%

T. Rowe Price Associates, Inc.

8.79%

JP Morgan Asset Management

6.50%

BlackRock Institutional Trust Company, N.A.

4.94%

Farallon Capital Management, L.L.C.

3.51%

Other

67.06%

Shareholder Types

Shareholders

Proportion

Investment Advisor

46.29%

Investment Advisor/Hedge Fund

27.68%

Hedge Fund

12.63%

Individual Investor

3.13%

Family Office

2.73%

Family Office

2.73%

Family Office

2.35%

Bank and Trust

1.98%

Research Firm

1.44%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

1137

131.96M

96.64%

-402.16K

2025Q1

1129

133.60M

97.90%

+2.21M

2024Q4

1001

128.40M

95.17%

-537.76K

2024Q3

896

125.06M

100.75%

-6.81M

2024Q2

850

125.13M

101.89%

-7.92M

2024Q1

798

124.30M

101.71%

-6.12M

2023Q4

781

119.55M

99.60%

-13.66M

2023Q3

787

122.52M

102.97%

-5.30M

2023Q2

792

116.72M

102.40%

-10.10M

2023Q1

788

115.81M

102.22%

-9.06M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

12.34M

9.04%

+53.13K

+0.43%

Mar 31, 2025

T. Rowe Price Associates, Inc.

10.43M

7.64%

+3.78M

+56.77%

Mar 31, 2025

JP Morgan Asset Management

6.39M

4.68%

+531.80K

+9.07%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.68M

4.89%

+212.90K

+3.29%

Mar 31, 2025

Farallon Capital Management, L.L.C.

4.55M

3.33%

+116.20K

+2.62%

Mar 31, 2025

State Street Global Advisors (US)

3.37M

2.47%

+379.58K

+12.69%

Mar 31, 2025

Duquesne Family Office LLC

3.40M

2.49%

-164.52K

-4.61%

Mar 31, 2025

Wellington Management Company, LLP

3.06M

2.24%

-180.35K

-5.57%

Mar 31, 2025

RTW Investments L.P.

2.59M

1.9%

+223.00

+0.01%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.39M

1.75%

+153.28K

+6.87%

Mar 31, 2025

Related ETFs

Updated: Sat, Sep 6

Name

Proportion

Alger Weatherbie Enduring Growth ETF

6.31%

Franklin Genomic Advancements ETF

5.47%

ARK Genomic Revolution ETF

4.61%

VanEck Biotech ETF

4.36%

Alger Mid Cap 40 ETF

3.52%

First Trust NYSE Arca Biotechnology Index Fund

3.51%

Global X Genomics & Biotechnology ETF

3.46%

TrueShares Technology, AI & Deep Learning ETF

3.3%

First Trust Nasdaq Lux Digi Health Solutions ETF

3.29%

FT Raymond James Multicap Growth Equity ETF

2.66%

Alger Weatherbie Enduring Growth ETF

Proportion6.31%

Franklin Genomic Advancements ETF

Proportion5.47%

ARK Genomic Revolution ETF

Proportion4.61%

VanEck Biotech ETF

Proportion4.36%

Alger Mid Cap 40 ETF

Proportion3.52%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.51%

Global X Genomics & Biotechnology ETF

Proportion3.46%

TrueShares Technology, AI & Deep Learning ETF

Proportion3.3%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proportion3.29%

FT Raymond James Multicap Growth Equity ETF

Proportion2.66%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

162.970USD

Natera Inc

162.970

Overview

Company

Financials

Analysis